Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension

Canadian Journal of Cardiology

Volumn 31, Issue 4, 2015, Pages 515-520

  Maron, Bradley A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; OXYHEMOGLOBIN; VASODILATOR AGENT;

ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART INDEX; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART SEPTUM DEFECT; HEART STROKE VOLUME; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; OXYGEN CONSUMPTION; PERICARDIAL EFFUSION; PHYSICAL EXAMINATION; PULMONARY ARTERY; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY ARTERY SYSTOLIC PRESSURE; PULMONARY HYPERTENSION; SURVIVAL; SYSTOLIC BLOOD PRESSURE; VENOUS OXYGEN TENSION; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; HEMODYNAMICS; HYPERTENSION, PULMONARY; META ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY;

EID: 84926160305     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.09.021     Document Type: Article

References (34)

1. Frank H., Hoop B., Poncelet B.P. Noninvasive measurement of pulmonary arterial blood velocity. Can it replace right heart catheterization?. Chest 1997, 111:1470-1471.
2. Hoeper M.M., Bogaard H.J., Condliffe R., et al. Definitions and diagnosis of pulmonary hypertension. JAm Coll Cardiol 2013, 62:D42-D50.
3. Naeije R., Vachiery J.L., Yerly P., et al. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Resp J 2013, 41:217-223.
4. Maron B.A., Choudhary G., Khan U.A., et al. Clinical profile and underdiagnosis of pulmonary hypertension in US veterans. Circ Heart Fail 2013, 6:906-912.
5. Deaño R.C., Glassner-Kolmin C., Rubenfire M., et al. Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. JAMA Intern Med 2013, 173:887-893.
6. Swiston J.R., Johnson S.R., Granton J.T. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. Resp Med 2010, 104:1588-1607.
7. Humbert M., Sitbon O., Chaouat A., et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122:156-163.
8. Benza R.L., Miller D.P., Gomberg-Maitland M., et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010, 122:164-172.
9. Frost A.E., Farber W.H., Barst R.J., et al. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mmHg: insights from the REVEAL Registry. Chest 2013, 143:185-195.
10. Platz E., Lattanzi A., Agbo C., et al. Utility of lung ultrasound in predicting pulmonary and cardiac pressures. Eur J Heart Fail 2012, 14:1276-1284.
11. Robbins I.M., Hemnes A.R., Pugh M.E., et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 2014, 7:116-122.
12. Sibton O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. JAm Coll Cardiol 2002, 40:780-788.
13. Provencher S., Sitbon O., Humbert M., et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006, 27:589-595.
14. Ghofrani H.A., Galié N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension. NEng J Med 2013, 369:330-340.
15. Tiede H., Sommer N., Milger K., et al. Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension. Pulm Circ 2013, 3:523-532.
16. Hoeper M.M., Humbert M., Torbicki A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Resp J 2009, 34:1219-1263.
17. Galié N., Corris P.A., Frost A., et al. Updated treatment algorithm of pulmonary arterial hypertension. JAm Coll Cardiol 2013, 62:D60-72.
18. Malhotra R., Hess D., Lewis G.D., et al. Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. Pulm Circ 2011, 1:250-258.
19. Oliveira R.K., Pereira C.A., Ramos R.P., et al. Ahaemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis. Eur Respir J 2014, 44:415-424.
20. Barst R.J., Rubin L.J., Long W.A., et al. Acomparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. NEng J Med 1996, 334:296-301.
21. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425-434.
22. Pulido T., Adzerikho I., Channick R.N., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. NEng J Med 2013, 369:809-818.
23. Hoeper M.M., Lett S.H., Voswinckel R., et al. Complication of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. JAm Coll Cardiol 2006, 48:2546-2552.
24. Opotowsky A.R., Ojeda J., Rogers F., et al. Asimple echocardiographic prediction rule for hemodynamics in pulmonary hypertension. Circ Cardiovasc Imag 2012, 5:765-775.
25. Opotowsky A.R., Clair M., Afialo J., et al. Asimple echocardiographic method to estimate pulmonary vascular resistance. Am J Cardiol 2013, 112:873-882.
26. Swift A.J., Rajaram S., Hurdman J., et al. Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. JACC Cardiovasc Imag 2013, 6:1036-1047.
27. Garćia-Alvarez A., Fernández-Friera L., Mirelis J., et al. Non-invasive estimation of pulmonary vascular resistance with cardiac magnetic resonance. Eur Heart J 2011, 32:2438-2445.
28. Yang T., Liang Y., Zhang Y., et al. Echocardiographic parameters in patietns with pulmonary arterial hpyeretnsion: correlates with right ventricular ejection fraction derived from cardiac magnetic resonance and hemodynamics. PLoS One 2013, 8:e71276.
29. Lang C.C., Karlin P., Haythe J., et al. Ease of noninvasive measurement of cardiac output coupled with peak VO2 determination at rest and during exercise in patients with heart failure. Am J Cardiol 2007, 99:404-405.
30. Farber H.W., Foreman A.J., Miller D.P., et al. REVEAL Registry: correlation of right heart catherization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail 2011, 17:56-63.
31. Ryan J.J., Butrous G., Maron B.A. The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts. Pulm Circ 2014, 4:441-451.
32. Fox B., Langleben D., Hirsch A.M., et al. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension. Can J Cardiol 2013, 29:672-677.
33. Luo N., Ryan J.J. Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition. Can J Cardiol 2013, 29:659-661.
34. Trinkmann F., Papvassiliu T., Kraus F., et al. Inert gas rebreathing: the effect of haemoglobin based pulmonary shunt flow correction on the accuracy of cardiac output measurements in clinical practice. Clin Physiol Funct Imaging 2009, 29:255-262.